In conclusion, this study is the first to reveal the pathophysiological roles of GPA in hepatic steatosis at the cellular and animal levels, suggesting the potential therapeutic applications of GPA in NAFLD and obesity-related metabolic diseases. This evidence concerns the gene GYPA and fatty liver disease.